RhumbLine Advisers
CYT

RhumbLine Advisers’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

RhumbLine Advisers’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,555
Closed -$47K – 3281
2022
Q1 		$47K Buy
+12,555
New +$71.5K ﹤0.01% 2978

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers's CYT Position: Q2 2022 in Review

RhumbLine Advisers sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2022, closing a stake of 12,555 shares — an estimated $47K sold.

RhumbLine Advisers first reported a position in CYT in Q1 2022 and held it in 1 quarter. The position peaked at $47K in Q1 2022. 45 funds tracked by Wall St. Rank hold CYT as of Q2 2022.

  • RhumbLine Advisers reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 12,555 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $47K.
  • RhumbLine Advisers first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • RhumbLine Advisers's Cyteir Therapeutics, Inc. Common Stock position peaked at $47K in Q1 2022.
  • 45 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.